In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carbonic acid lithium salt (Li2CO3) Drug Master File in Korea (Carbonic acid lithium salt (Li2CO3) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carbonic acid lithium salt (Li2CO3). The MFDS reviews the Carbonic acid lithium salt (Li2CO3) KDMF as part of the drug registration process and uses the information provided in the Carbonic acid lithium salt (Li2CO3) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carbonic acid lithium salt (Li2CO3) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carbonic acid lithium salt (Li2CO3) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carbonic acid lithium salt (Li2CO3) suppliers with KDMF on PharmaCompass.